Lipopolysaccharide chemotypes of Burkholderia cepacia

Journal of Medical Microbiology

Volumn 48, Issue 9, 1999, Pages 825-832

  Evans, Elwyn ^a   Poxton, Ian R ^a   Govan, John R W ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; VIRULENCE FACTOR;

ARTICLE; BACTERIAL VIRULENCE; BURKHOLDERIA CEPACIA; CROSS REACTION; IMMUNOBLOTTING; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL;

EID: 0032879192     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/00222615-48-9-825     Document Type: Article

References (25)

1. 1. Govan JRW, Hughes JE, Vandamme P. Burkholderia cepacia: medical taxonomic and ecological issues. J Med Microbiol 1996; 45: 395-407.
2. 2. Isles A, Maclusky I, Corey M et al. Pseudomonas cepacia infection in cystic fibrosis: an emerging problem. J Pediatr 1984; 104: 206-210.
3. 3. Lewin C, Doherty C, Govan J. In vitro activity of meropenem, PD 127391, PD 131628, ceftazidime, chloramphenicol, cotrimoxazole and ciprofloxacin against Pseudomonas cepacia. Antimicrob Agents Chemother 1993; 37: 123-125.
4. 4. Govan JRW, Brown PH, Maddison J et al. Evidence for transmission of Pseudomonas cepacia by social contact in cystic fibrosis. Lancet 1993; 342: 15-19.
5. 5. Nelson JW, Butler SL, Brown PH, Greening AP, Govan JRW. Serum IgG and sputum IgA antibody to core lipopolysaccharide antigen from Pseudomonas cepacia in patients with cystic fibrosis. J Med Microbiol 1993; 39: 39-47.
6. 6. Aronoff SC, Quinn FJ, Stern RC. Longitudinal serum IgG response to Pseudomonas cepacia surface antigens in cystic fibrosis. Pediatr Pulmonol 1991; 11: 289-293.
7. 7. Nelson JW, Butler SL, Krieg D, Govan JRW. Virulence factors of Burkholderia cepacia. FEMS Immunol Med Microbiol 1994; 8: 89-97.
8. 8. Hutchison ML, Poxlon IR, Govan JRW. Burkholderia cepacia produces a hemolysin that is capable of inducing apoptosis and degranulation of mammalian phagocytes. Infect Immun 1998; 66: 2033-2039.
9. 9. Reitschel ET, Kirikae T, Schade FU et al. The chemical structure of bacterial endotoxin in relation to bioactivity. Imnumobiology 1993; 187: 169-190.
10. 10. Greally P, Hussein MJ, Cook AJ, Sampson AP, Piper PJ, Price JF. Sputum tumour necrosis factor-α and leukotriene concentrations in cystic fibrosis. Arch Dis Child 1993; 68: 389-392.
11. 11. Shaw D, Poxton IR, Govan JRW. Biological activity of Burkholderia (Pseudomonas) cepacia lipopolysaccharide. FEMS Immunol Med Microbiol 1995; 11: 99-106.
12. 12. Hughes JE, Stewart J, Barclay GR, Govan JRW. Priming of neutrophil respiratory burst activity by lipopolysaccharide from Burkholderia cepacia. Infect Immun 1997; 65: 4281-4287.
13. 13. Yabuuchi E, Kosako Y, Oyaizu H et al. Proposal of Burkholderia gen, nov. and transfer of seven species of the genus Pseudomonas homology group II to the new genus, with the type species Burkholderia cepacia (Palleroni and Holmes 1981) comb. nov. Microbiol Immunol 1992; 36: 1251-1275.
14. 14. Vandamme P. Emerging new 'Pseudomonas' species in cystic fibrosis. 20th European Cystic Fibrosis Conference, Brussels. 1995, L1.
15. 15. Vandamme P, Holmes B, Vancannyet M et al. Occurrence of multiple genomovars of Burkholderia cepacia in cystic fibrosis patients and proposal of Burkholderia multivorans sp. nov. Int J Syst Bacteriol 1997; 47: 1188-1200.
16. 2 fixing isolates from rice in Vietnam. Int J Syst Bacteriol 1995; 45: 274-289.
17. 17. Goldberg JB, Pier GB. Pseudomonas aeruginosa lipopolysaccharides and pathogenesis. Trends Microbiol 1996; 4: 490-494.
18. 18. Evans E, Brown MRW, Gilbert P. Iron chelator, exopolysaccharide and protease production in Staphylococcus epidermidis: A comparative study of the effects of specific growth rate in biofilm and planktonic culture. Microbiology 1994; 140: 153-157.
19. 19. Butler SL, Doherty CJ, Hughes JF, Nelson JW, Govan JRW. Burkholderia cepacia and cystic fibrosis: do natural environments present a potential hazard? J Clin Microbiol 1995; 33: 1001-1004.
20. 20. Hancock I, Poxton I. Bacterial cell surface techniques. Chichester, John Wylie and Sons, 1988.
21. 21. Fomsgaard A, Strand GH, Freudenberg MA et al. Antibodies from chronically infected cystic fibrosis patients react with lipopolysaccharides extracted by new micromethods from all serotypes of Pseudomonas aeruginosa. APMIS 1993; 101: 101-112.
22. 22. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 1979; 76: 4350-4354.
23. 23. Govan JRW, Deretic V. Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia, Microbiol Rev 1996; 60: 539-574.
24. 24. Larsen GY, Skull TL, Bums JL. Marked phenotypic variability in Pseudomonas cepacia from a patient with cystic fibrosis. J Clin Microbiol 1993; 31: 788-792.
25. 25. Costerton JW, Irvin RT, Cheng KJ. The bacterial glycocalyx in nature and disease. Annu Rev Microbiol 1981; 35: 299-324.